《大行報告》瑞信降平安好醫生(01833.HK)評級至「跑輸大市」 目標價輕微下調至18元
瑞信發表評級報告指,由於平安好醫生(01833.HK)正進行「戰略2.0」轉型,預料今年收入按年錄得低雙位數下跌,該行認為此次業務轉型仍需時完成,故對公司短期收入增長有所影響。
該行表示,即使公司今年全年整體盈利能力或有所改善,惟毛利率仍需時改善,尤其部分利潤率較高的業務,如健康服務等。該行指公司目標在2024年達致收支平衡。
該行將公司今年、明年及2024年收入預測下調17%、14%及14%、淨虧損預測則下調11%、14%及24%,並將其目標價由18.1元輕微下調至18元,評級由「中性」降至「跑輸大市」。(ca/u)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.